budesonide/formoterol / Generic mfg. - LARVOL DELTA

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on clinical remission in inadequately controlled asthma: post hoc analyses of KALOS and LOGOS studies (ERS 2026) - "Background: The Phase 3 KALOS and LOGOS studies in uncontrolled asthma showed improved lung function and exacerbation rates with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) in an Aerosphere® MDI vs combined budesonide/formoterol fumarate dihydrate (Aerosphere® MDI, BFFA; or Symbicort®, BFFS)... BGF 28.8 triple therapy improved odds of clinical remission over BFF dual therapy in participants with uncontrolled asthma."

Clinical • Retrospective data • Asthma • Immunology • Respiratory Diseases

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on lung function and asthma exacerbations by persistent airflow limitation status: post hoc analyses of KALOS and LOGOS studies (ERS 2026) - "The KALOS and LOGOS studies in inadequately controlled asthma showed improved LF and exacerbation rates with budesonide/glycopyrronium/formoterol fumarate dihydrate via Aerosphere® MDI (BGF 28.8; 320/28.8/10 µg) vs combined budesonide/formoterol fumarate dihydrate (BFFCombined) via Aerosphere® MDI (BFFA) or Symbicort® (BFFS)... BGF 28.8 showed benefits over BFFCombined with improved LF and reduced severe exacerbations irrespective of PAL status."

Retrospective data • Asthma • Immunology • Respiratory Diseases

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on time to first clinically important deterioration and number needed to treat for clinically important deterioration rate: tertiary analyses of KALOS and LOGOS studies (ERS 2026) - "Background: KALOS and LOGOS studies in uncontrolled asthma showed improved lung function with budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF 28.8; 320/28.8/10 µg) vs combined budesonide/formoterol fumarate dihydrate (Aerosphere® MDI, BFFA; or Symbicort®, BFFS)... BGF 28.8 prolonged time to first CID with a low NNT vs either BFF formulation, highlighting the benefits of BGF as a treatment option in uncontrolled asthma."

Clinical • Asthma • Immunology • Respiratory Diseases

Fidelity to Maintenance and Reliever Therapy (MART) in Paediatric Asthma: A Mixed Methods Study of Prescription Consistency in Clinical Practice (ERS 2026) - "Methods We conducted a mixed-methods service evaluation including 5–18-year-old patients prescribed Symbicort® MART in a tertiary paediatric respiratory clinic...Conclusions Fidelity to MART prescribing in paediatric asthma is suboptimal. Standardised letters, enhanced GP education, and family support are essential to strengthen implementation and reduce preventable exacerbations."

Clinical • Asthma • Immunology • Pediatrics • Respiratory Diseases

An evaluation of the impact of new asthma guidelines on prescribing practice and acute hospital attendance across Hampshire and the Isle of Wight. (ERS 2026) - "Monthly Symbicort prescriptions increased from 691 to 1017 (p<0.001 for all outcomes)... These initial data demonstrate significant improvements in prescribing and decreased numbers of acute wheeze. Work is ongoing to further implement best practice guidance across our locality."

Clinical • Asthma • Immunology • Respiratory Diseases

Deposition of three dry powder aerosol drugs in the airways of severe asthma patients undergoing biological therapy (ERS 2026) - "This study aimed to quantify the deposition patterns of the fixed‑combination dry powder inhalers Symbicort® Turbuhaler®, Foster® NEXThaler®, and Relvar® Ellipta® in the airways of these patients. Conclusions The vast majority of severe asthmatics receiving biologic therapy were able to generate inhalation parameters sufficient to achieve an adequate delivered lung dose. Overall, patients with lower PIF values through the inhaler achieved higher lung deposition with Relvar and Foster, while those with high PIF values obtained the greatest lung doses with Foster and Symbicort."

Clinical • Asthma • Immunology • Respiratory Diseases

Efficacy of Inhaled Corticosteroid/Long Acting Beta-agonist on Post Infectious Cough: A Pilot Study (ERS 2026) - "All participants were treated with ICS/LABA (Symbicort or Relvar) up to 4 weeks with a weekly telephone follow-up... ICS/LABA has been proven safe for patients with post-infectious cough in our study, showing rapid improvement from day 7 to day 28. A RCT is warranted to explore its clinical use."

Clinical • Asthma • Chronic Obstructive Pulmonary Disease • Cough • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases

COMPAIR: A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (clinicaltrials.gov) - P1 | N=16 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed | Trial completion date: Oct 2026 ➔ Jun 2026 | Trial primary completion date: Oct 2026 ➔ Jun 2026

Trial completion • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Rosai-Dorfman Disease Presenting as a Subglottic Mass (AHNS 2026) - "The patient was being followed by pulmonology, where she was prescribed Symbicort and Albuterol as needed. Upon arrival at the emergency department, she was given Prednisone, Duonebs, and racemic epinephrine nebulization with minimal improvement...However, some cases may show spontaneous regression, but treatments that have been shown to improve symptoms are surgery, steroids, radiation, chemotherapy, Sirolimus, and immunomodulators (2)... In conclusion we present a 59-year-old female with worsening airway symptoms who was shown to have Rosai-Dorfman Disease with isolated subglottic involvement. Her symptoms improved following debulking surgery, and she was discharged home in good condition. She was decannulated one month after discharge."

Hematological Malignancies • Infectious Disease • Laryngeal Cancer • Lymphoma • Otorhinolaryngology • Pneumonia • Pulmonary Disease • Rare Diseases • Respiratory Diseases • Solid Tumor

Assessing the Equitable Use of Formulary Drug Tier Systems: Consequences for Geriatric Patient Population Access and Accessible Medication. (PubMed, Innov Pharm) - "For example, Alzheimer's medications like galantamine and rivastigmine were found in higher tiers, leading to increased out-of-pocket expenses, while COPD treatments such as Symbicort and Trelegy Ellipta, although in preferred tiers, still imposed significant financial burdens. Rheumatoid arthritis drugs showed a wide cost range, with Humira in Tier 5 presenting the highest financial challenge. Similarly, ischemic heart disease and type 2 diabetes medications varied in affordability, with drugs like Eliquis and Steglatro positioned in higher tiers, significantly impacting patient costs and potential treatment adherence...The results highlight the pressing requirement for more effective policy actions that support price transparency, promote the utilization of cost-effective generics, and deter the unwarranted classification of generic drugs in higher formulary tiers."

Journal • Alzheimer's Disease • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Coronary Artery Disease • Dementia • Diabetes • Geriatric Disorders • Heart Failure • Immunology • Inflammatory Arthritis • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Type 2 Diabetes Mellitus

COMPAIR: A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (clinicaltrials.gov) - P1 | N=15 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Cryptococcal laryngitis in immunocompetent patients on steroid inhalers: a case series (COSM 2026) - " The first patient, a 72-year-old male with asthma on Symbicort (budesonide-formeterol) and renal cell carcinoma on immunotherapy presented with over 1 year of cough and dysphonia...The third patient, a 48-year-old female with asthma on Trelegy (fluticasone-umeclidin-vilant) and eosinophilic esophagitis on Nucala, presented with 6 months of dysphonia and cough...She was referred to infectious disease and improved with ciprofloxacin and long-term, high-dose oral fluconazole... We present three cases of cryptococcal laryngitis in immunocompetent patients using newer generation inhaled corticosteroids. These agents may disrupt mucosal barriers, increasing susceptibility to opportunistic fungal infection. Operative biopsy and referral to infectious disease should be considered when symptoms persist despite initial therapy."

Clinical • Asthma • CNS Disorders • Cough • Dysphonia • Eosinophilic Esophagitis • Gastrointestinal Disorder • Genito-urinary Cancer • Immunology • Infectious Disease • Otorhinolaryngology • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor

Hidden Dangers of Inhaled Corticosteroids: A Case of Budesonide-Induced Adrenal Suppression in a Female with COPD (AACE 2026) - "Case Description A 43-year-old transgender woman on estradiol hormone therapy with a history of COPD and well-controlled HIV on bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) presented to the emergency department with progressive shortness of breath...Although hospitalized, where she received only standard twice daily budesonide/formoterol (Symbicort), she developed Discussion Secondary adrenal insufficiency from inhaled corticosteroids is rare and often overlooked, but can occur with prolonged high-dose exposure, particularly with potent agents like budesonide. This case highlights the importance of recognizing that inhaled corticosteroids, although generally considered safer than systemic steroids, can still suppress the hypothalamic-pituitary-adrenal axis when used excessively or frequently. Patients with chronic respiratory illness may escalate inhaler use during"

Clinical • Chronic Obstructive Pulmonary Disease • Endocrine Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Nephrology • Renal Disease • Respiratory Diseases

Budesonide/glycopyrronium/formoterol fumarate dihydrate triple therapy for inadequately-controlled asthma: KALOS and LOGOS study results (TSANZSRS 2026) - "KALOS and LOGOS, two Phase 3, double-blind, double-dummy randomised studies, compared fixed-dose triple combination budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) with budesonide/formoterol fumarate dihydrate metered-dose inhaler (MDI; BFF) and pressurised MDI ([Symbicort®] BUD/FORM)...AE frequency was comparable across treatments arms. BGF 320/28.8/10µg is superior to ICS/LABA in adults and adolescents with asthma inadequately-controlled by ICS/LABA"

Asthma • Immunology • Respiratory Diseases

START CARE: A Randomised Controlled Trial of the efficacy and safety of an Inhaled Corticosteroid and Long Acting Beta Agonist maintenance and/or reliever therapy versus standard maintenance with separate reliever therapy in children with mild, moderate and severe asthma. (ANZCTR) - P3 | N=400 | Completed | Sponsor: Medical Research Institute of New Zealand | Active, not recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Prediction of site-specific drug deposition via dry powder inhaler using non-invasive real-time particle emission signal monitoring system. (PubMed, Front Pharmacol) - "Oropharyngeal deposition correlated with flow rate at particle emission peak, fitting a linear model (R 2 = 0.82), consistent with inertial impaction mechanisms. Using an in-vitro model, particle emission signals enable the prediction of site-specific drug deposition from DPI, providing non-invasive, real-time indices and offering personalized inhalation performance assessment beyond conventional flow rate metrics."

Journal

COMPAIR: A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Budesonide/Glycopyrrolate/Formoterol Fumarate Effects on Lung Function and Exacerbations by Baseline Exacerbation History in Inadequately Controlled Asthma: Post Hoc Analyses of KALOS and LOGOS Studies (AAAAI 2026) - "Rationale KALOS and LOGOS compared budesonide/glycopyrrolate/formoterol fumarate (BGF) with budesonide/formoterol fumarate (BFF) or Symbicort® (BUD/FORM) administered via metered-dose inhaler...Annualized pooled exacerbation risk (rate ratio [95% CI]) favored BGF 36 versus BUD/FORM for 0 (0.82 [0.65, 1.03], p=0.087) and ≥1 (0.81 [0.68, 0.96], p=0.017) baseline exacerbations. Conclusions BGF 36 improved lung function and reduced exacerbation risk versus BUD/FORM, with similar treatment effects regardless of whether participants had exacerbations in the 12 months prior to enrollment."

Retrospective data • Asthma • Immunology • Respiratory Diseases

Fluticasone- vs Budesonide-Based Dual Therapy for COPD. (PubMed, JAMA Netw Open) - "In this cohort study of new ICS-LABA users with COPD, once-daily dry powder fluticasone furoate-vilanterol inhalers were associated with slightly improved clinical outcomes compared with twice-daily metered-dose budesonide-formoterol inhalers and twice-daily dry powder fluticasone propionate-salmeterol inhalers. Further studies are needed to explore potential intraclass differences among inhalers used to treat COPD."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

COMPAIR: A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Ventilation and Perfusion in Asthmatics (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: University of Miami

New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. (PubMed, Lancet Respir Med) - P3 | "These findings show that BGF improves lung function and reduces severe exacerbation rates in a broad population with asthma inadequately controlled despite medium-dose or high-dose ICS-LABA use. Given that these findings were observed regardless of recent exacerbation history, BGF could benefit individuals with inadequately controlled asthma without requiring a recent episode of acute deterioration on ICS-LABA before escalation."

Journal • P3 data • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

TWO CASES OF ASTHMA INDUCED BY SMOKE FROM BURNING RICE STRAWS AND RICE HUSKS (PubMed, Arerugi) - "The peripheral eosinophil counts and fractional exhaled nitric oxide levels were not elevated, indicating no association with eosinophilic airway inflammation. Symbicort maintenance and reliever therapy was effective in reducing the systemic steroid dose in both cases."

Journal • Asthma • Cough • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

ARRIVAL: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (clinicaltrials.gov) - P3 | N=296 | Active, not recruiting | Sponsor: AstraZeneca | Recruiting ➔ Active, not recruiting

Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Safety Assessment of Budesonide/Formoterol: Real-World Pharmacovigilance Analysis Using the FAERS, JADER, and CVAR Databases. (PubMed, Clin Ther) - "This multi-database analysis highlights the need for continuous pharmacovigilance for budesonide/formoterol. The identification of novel ADE signals emphasizes the importance of vigilant monitoring, especially during early treatment, to enhance safety and therapeutic outcomes."

Adverse events • Journal • Real-world evidence • Alopecia • Alzheimer's Disease • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • CNS Disorders • Cough • Dysphonia • Endocrine Disorders • Hepatology • Immunology • Infectious Disease • Liver Failure • Myocardial Infarction • Pneumonia • Pulmonary Disease • Respiratory Diseases